Novavax
NVAX
#5787
Rank
$1.10 B
Marketcap
$6.78
Share price
-1.88%
Change (1 day)
-25.25%
Change (1 year)

Novavax (NVAX) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : $1.33 Billion USD

According to Novavax's latest financial reports the company's total liabilities are $1.33 Billion USD. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novavax - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31$2.18 B-13.13%
2023-12-31$2.51 B-13.08%
2022-12-31$2.89 B-1.22%
2021-12-31$2.92 B206.55%
2020-12-31$0.95 B166.11%
2019-12-31$0.35 B-4.51%
2018-12-31$0.37 B-7%
2017-12-31$0.40 B1.09%
2016-12-31$0.39 B328.24%
2015-12-31$93.36 M101.3%
2014-12-31$46.38 M45.45%
2013-12-31$31.89 M44.27%
2012-12-31$22.1 M73.69%
2011-12-31$12.72 M-19.42%
2010-12-31$15.79 M0.9%
2009-12-31$15.65 M-49.73%
2008-12-31$31.13 M10.31%
2007-12-31$28.22 M1.26%
2006-12-31$27.87 M-19.74%
2005-12-31$34.73 M-22.33%
2004-12-31$44.71 M-7.27%
2003-12-31$48.21 M-2.46%
2002-12-31$49.43 M24.76%
2001-12-31$39.62 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Agenus
AGEN
$0.51 B-61.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
$2.17 B 62.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
$0.87 B-34.27%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
$0.83 B-37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
$68.48 B 5,023.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
$115.63 B 8,551.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
$62.53 B 4,578.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NanoViricides
NNVC
$1.3 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
$61.28 B 4,485.23%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
$50.07 M-96.25%๐Ÿ‡บ๐Ÿ‡ธ USA